The recognition of LY6E as a potential focus for cancer treatment has driven considerable effort. Various therapeutic candidates are currently developed with the purpose of directly inhibiting LY6E's activity and promoting an antitumor response in patients suffering with various cancers . Challenges remain in optimizing antibody administration and